ClinicalTrials.gg
CompletedNCT05633407POTSUpdated May 23, 2025Results posted

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

A Phase 2 interventional study of Efgartigimod and Placebo in Postural Orthostatic Tachycardia Syndrome, sponsored by argenx. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.

Enrollment
18th of 67
53 · median 36
Started
2022
with 9 others
Phase 2
10 of 92
3 open now
Registered
67th of 92
by date
Lead sponsor
2 of 92
argenx

Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 18th largest by enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2022, is one of 10 in phase 2, and was the 67th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, or all of them as a file.
02

Study summary

The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).

Read the detailed description

The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS). Efgartigimod may be a viable treatment option for individuals diagnosed with post-COVID-19 POTS because it has been shown to reduce IgG levels, including IgG autoantibodies, which may underlie some of the autonomic disease manifestations in these patients.

03

Conditions studied

  • Postural Orthostatic Tachycardia Syndrome

Keywords

  • POTS
  • Long COVID
  • Postural Orthostatic Tachycardia Syndrome
  • efgartigimod
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Reached the age of consent when signing the form
  2. Capable of providing signed informed consent and complying with protocol requirements
  3. Diagnosed with new-onset POTS post-COVID-19 established by the following:

    1. History of COVID-19 based on a previous positive test result from either laboratory-confirmed COVID-19 test (eg, a PCR test) or non-laboratory-confirmed COVID-19 test (eg, rapid antigen test); this positive result may be either documented or patient-reported
    2. Tilt table or orthostatic vital sign measurements during screening consistent with consensus criteria: sustained HR increase of ≥30 bpm within 10 min of standing or head up tilt (≥40 bpm for individuals aged 18 to 19 years) and/or HR reaching >120 bpm within 10 min; absence of sustained 20 mmHg decrease in systolic blood pressure (SBP)
    3. Ongoing symptoms of POTS confirmed by the investigator with at least 3 symptoms in each of the following areas lasting longer than 12 weeks after either diagnosis of COVID-19 or after hospital discharge for COVID-19:

    i. Vasomotor symptoms: fatigue, orthostatic intolerance, brain fog, exertional dyspnea, difficulty with concentration, venous pooling, and exercise intolerance ii. Sympathetic over-compensation symptoms: palpitation, heat intolerance, nausea with or without vomiting, insomnia, anxiety, lack of appetite, chest pain, and diaphoresis

  4. COMPASS 31 ≥35 at screening
  5. Agree to use consistent with local regulations regarding the methods of contraception for those participating in clinical studies and the following:

    Male participants: No male contraception is required Female participants of must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before receiving IMP. Contraceptive requirements.

  6. (BMI) \<35 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of or receiving treatment for the following conditions before COVID-19: peripheral neuropathy, POTS, myalgic encephalomyelitis encephalitis/chronic fatigue syndrome, Ehlers Danlos syndrome confirmed by genetic testing, autonomic neuropathy, multiple sclerosis, stroke, spinal cord injury, or any known lesions in the central nervous system by imaging or neurological exam
  2. History of or currently being treated for ongoing cardiac arrythmia, heart failure, myocarditis, pulmonary embolism requiring anticoagulation, pulmonary fibrosis, or critical illness-related polyneuropathy or myopathy
  3. Known disease that, in the investigator's judgment, would interfere with an accurate assessment of clinical symptoms of post-COVID-19 POTS or puts the participant at undue risk
  4. Known disease or common variable immunodeficiency
  5. History of unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of IMP. Adequately-treated participants with the following cancers may be included at any time:

    1. Basal cell or squamous cell skin cancer
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast
    4. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
  6. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection or positive SARS-CoV-2 PCR test at screening
  7. Positive serum test at screening for an active infection with any of the following:

    1. virus (HBV) that is indicative of an acute or chronic infection, unless associated with a negative HB surface antigen (HBsAg) or negative HBV DNA test
    2. virus (HCV) based on HCV antibody assay unless a negative RNA test is available
    3. HIV
  8. A medical condition that could confound the results of the study or put the participant at undue risk in the investigator's judgment
  9. Clinically significant disease, recent major surgery (within 3 months of screening), or intends to have surgery during the study; or any other condition that in the opinion of the investigator could confound the results of the study or put the participant at undue risk
  10. Total IgG \<4 g/L at screening
  11. Received within 12 weeks or 5 half-lives (whichever is longer) before screening an product
  12. Received within 12 weeks before screening either intravenous immunoglobulin (Ig) IV or SC or plasmapheresis/plasma exchange (PLEX)
  13. Received a live or less than 4 weeks before screening
  14. Known to IMP or 1 of its
  15. Previously participated in an efgartigimod clinical study and received at least 1 dose of IMP
  16. Currently participating in another interventional clinical study
  17. History (within 12 months of screening) of or current alcohol, drug, or medication abuse
  18. Pregnant or lactating or intends to become pregnant during the study
  19. Unwilling to remain on a stable regimen of medications during the study
  20. Unwilling to avoid initiation of new physical rehabilitation or other physician-prescribed exercise programs during the 24-week treatment period
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Efgartigimod

    Receive efgartigimod IV 10mg/kg during weekly infusions during a treatment period of 24 weeks

    Drug: Efgartigimod

  • Placebo comparator
    Placebo

    Receive a matching placebo during weekly infusions during a treatment period of 24 weeks

    Drug: Placebo

Interventions

  • Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively

  • DrugPlacebo

    Receive a matching placebo during weekly infusions during a treatment period of 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version)

    Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.

    Time frame: Baseline (Day 1) and Week 24

  2. Change From Baseline to Week 24 in the MaPS

    The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a visual analog scale ranging from 0 (no symptoms) to 10 (worst possible). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.

    Time frame: Baseline (Day 1) and Week 24

  3. Number of Participants With TEAEs and TESAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.

    Time frame: From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 236 days

Secondary outcomes

  1. Percentage of Participants With Improved PGI-S at Week 24

    The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.

    Time frame: Baseline (Day 1) and Week 24

  2. Percentage of Participants With Improved in PGI-C at Week 24

    The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of a change in their overall symptom severity. Overall change in symptoms was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.

    Time frame: Baseline (Day 1) and Week 24

  3. Change From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.

    Time frame: Baseline (Day 1) and Week 24

  4. Change From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a

    PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.

    Time frame: Baseline (Day 1) and Week 24

  5. Percent Change From Baseline in Total IgG Levels at Week 24

    Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.

    Time frame: Baseline (Day 1) and Week 24

  6. Serum Concentration of Efgartigimod

    Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.

    Time frame: Pre-dose and post-dose at Baseline (Day 1), Weeks 1, 4, 12 and at Week 24

  7. Number of Participants With ADAs Against Efgartigimod

    Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.

    Time frame: Up to Week 24

07

Results

Posted May 23, 2025

Participant flow

This phase 2, randomized, double-blind study was conducted at 11 sites in the United States from 23-Sep-22 to 18-Apr-24 in participants with post-coronavirus disease 2019 (COVID-19) postural orthostatic tachycardia syndrome (POTS).

Participant flow — Overall Study
MilestoneEfgartigimodPlacebo
Started3617
Completed3116
Not completed51
Withdrew: Physician decision20
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Withdrew: Other11

Outcome measures

PrimaryChange From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version)

Composite Autonomic Symptom Score (COMPASS) 31 modified version (2-week recall) is a self-rated questionnaire to evaluate the severity and distribution of autonomic symptoms in various autonomic nerve disorders. It consists of 31 questions in 6 weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal {GI}-mixed upper and diarrhea, bladder, and pupillomotor). A weighted total score of 0 (mild) to 100 (severe) was determined by adding a maximum raw score for each domain. Higher scores indicated a more severe degree of autonomic symptoms.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version)
score on a scaleEfgartigimodPlacebo
Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version)-14.369 ± 15.2541-15.957 ± 17.2963
PrimaryChange From Baseline to Week 24 in the MaPS

The Malmö POTS Symptom Score (MaPS) score is a dedicated POTS symptom scoring questionnaire. The score consists of 12 questions that assess symptom burden related (tachycardia, palpitations, dizziness, presyncope) and unrelated to orthostatic intolerance (GI symptoms, insomnia, concentration difficulties). Participants graded their symptoms for the past 7 days using a visual analog scale ranging from 0 (no symptoms) to 10 (worst possible). The total score was calculated by summing up the items/individual items and range was 0 to 120 points, with higher scores indicating more severe symptoms.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Week 24 in the MaPS
score on a scaleEfgartigimodPlacebo
Change From Baseline to Week 24 in the MaPS-23.5 ± 25.87-19.8 ± 27.75
PrimaryNumber of Participants With TEAEs and TESAEs

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration.

Time frame:
From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 236 days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs
ParticipantsEfgartigimodPlacebo
TEAEs3114
TESAEs00
SecondaryPercentage of Participants With Improved PGI-S at Week 24

The Patient Global Impression-Severity (PGI-S) is a participant-rated, single-item scale to assess the severity of a health condition. The scale was used to assess the severity of symptoms over the past week (1-week recall) and overall experience of symptoms over the past 2 weeks (2-week recall). Both were rated on a 4-point type Likert scale, with scores ranging from 1 (none), 2 (mild), 3 (moderate), and 4 (severe). Higher scores indicate greater symptom severity. An "improved PGI-S" was defined by a change from baseline of -3, -2 and -1.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improved PGI-S at Week 24
percentage of participantsEfgartigimodPlacebo
1-week recall45.553.3
2-week recall54.533.3
SecondaryPercentage of Participants With Improved in PGI-C at Week 24

The Patient Global Impression-Change (PGIC) is a single-item scale to capture the participant's perception of a change in their overall symptom severity. Overall change in symptoms was rated on a 7-point Likert scale, with scores ranging from 1 (much better), 2 (somewhat better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (somewhat worse), and 7 (much worse). Higher PGI-C scores signify worse outcome. An "improved PGI-C" was defined by a change from baseline of 1, 2 and 3.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improved in PGI-C at Week 24
percentage of participantsEfgartigimodPlacebo
Percentage of Participants With Improved in PGI-C at Week 2465.453.3
SecondaryChange From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a

The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a assesses the impact and perceived fatigue during the last 7 days. This validated 8-question scale has 5 response options, with scores ranging from 1 (not at all) to 5 (very much). Total scores ranged from 8 to 40; higher scores indicated higher fatigue levels and were converted to a T-score with a mean of 50 and standard deviation of 10. A decrease in T-score (negative change from baseline) indicated improvement in fatigue.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · T-score
Change From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a
T-scoreEfgartigimodPlacebo
Change From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a-9.5 ± 8.77-7.0 ± 9.40
SecondaryChange From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a

PROMIS Cognitive Function Short Form 6a assesses the frequency of cognitive difficulties experienced in the past 7 days. The questionnaire comprises 6 questions on subjective cognitive difficulties regarding a participant's concentration, memory, language, mental acuity, and perceived changes in cognitive functioning. The participant marks their response on a 5-point Likert scale (1: never and 5: very often). Scores ranged from 6 to 30; higher scores indicated worse perceived cognitive functioning and were converted to a T-score with a mean of 50 and standard deviation of 10. An increase in T-score (positive change from baseline) indicated better cognitive function.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · T-score
Change From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a
T-scoreEfgartigimodPlacebo
Change From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a3.9 ± 9.586.7 ± 9.74
SecondaryPercent Change From Baseline in Total IgG Levels at Week 24

Blood samples for immunoglobulin G (IgG) analysis were collected at specified time points. Total IgG concentrations were quantified using validated methods at a central laboratory.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Total IgG Levels at Week 24
percent changeEfgartigimodPlacebo
Percent Change From Baseline in Total IgG Levels at Week 24-69.341 ± 6.06375.868 ± 13.1379
SecondarySerum Concentration of Efgartigimod

Serum samples were collected at specified timepoints to determine the concentration of efgartigimod.

Time frame:
Pre-dose and post-dose at Baseline (Day 1), Weeks 1, 4, 12 and at Week 24
Reported as:
Mean · nanogram (ng)/mL
Serum Concentration of Efgartigimod
nanogram (ng)/mLEfgartigimod
Baseline, pre-doseNA ± NA
Baseline, post-dose260536 ± 235110
Week 1, pre-dose10711 ± 3580
Week 1, post-dose235100 ± 68316
Week 4, pre-dose12612 ± 5631
Week 4, post-dose230308 ± 54329
Week 12, pre-dose18966 ± 39993
Week 12, post-dose216760 ± 56621
Week 2410450 ± 3894
SecondaryNumber of Participants With ADAs Against Efgartigimod

Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With ADAs Against Efgartigimod
ParticipantsEfgartigimodPlacebo
Number of Participants With ADAs Against Efgartigimod51

Adverse events

Collected over From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 236 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod0/36 (0%)0/36 (0%)31/36 (86.1%)
Placebo0/17 (0%)0/17 (0%)14/17 (82.4%)
Most frequent other events
Showing 10 of 77
Most frequent other events
EventEfgartigimodPlacebo
FatigueGeneral disorders10/363/17
HeadacheNervous system disorders10/363/17
NauseaGastrointestinal disorders7/364/17
VomitingGastrointestinal disorders0/363/17
MyalgiaMusculoskeletal and connective tissue disorders3/363/17
DizzinessNervous system disorders3/363/17
Nasal congestionRespiratory, thoracic and mediastinal disorders3/363/17
Urinary tract infectionInfections and infestations5/361/17
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/362/17
ConstipationGastrointestinal disorders1/362/17

Baseline characteristics

Analysis was performed on full analysis set (FAS) which included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)EfgartigimodPlaceboTotal
Mean38.4 ± 12.8236.8 ± 11.9937.9 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)EfgartigimodPlaceboTotal
Female301545
Male628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EfgartigimodPlaceboTotal
Hispanic or Latino336
Not Hispanic or Latino331346
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EfgartigimodPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American101
White331750
More than one race101
Unknown or Not Reported000
08

Study locations

11 sites
  • University of California, San Diego Sulpizio Cardiovascular Center
    La Jolla, California 92037, United States
  • Stanford Movement Disorder Center
    Palo Alto, California 94304, United States
  • Northshore University Health System
    Glenview, Illinois 60026, United States
  • Johns Hopkins University
    Baltimore, Maryland 21224, United States
  • Harvard Medical School, Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Vandetbilt University Medical Center / Clinical Research Center
    Nashville, Tennessee 37232, United States
  • Apex Trials Croup, LLC
    Fort Worth, Texas 76132, United States
  • Texas Institute of Cardiology
    McKinney, Texas 75071, United States
  • Pioneer Clinical Research
    Rosharon, Texas 77583, United States
  • Metrodora Institute
    West Valley City, Utah 84119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2024, 18 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Dec 1, 2022
StartActual
Sep 23, 2022
Primary completionActual
Apr 18, 2024
CompletionActual
Apr 18, 2024
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05633407
Lead sponsor
argenx
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Sep 23, 2022
Primary completion
Apr 18, 2024
Completion
Apr 18, 2024
Results posted
May 23, 2025
Last update
May 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion